Plus Therapeutics (PSTV) EPS (Weighted Average and Diluted) (2010 - 2026)
Plus Therapeutics (PSTV) reported EPS (Weighted Average and Diluted) of -$1.05 for Q1 2026, up 96.48% year-over-year from -$0.53 in Q1 2025, and down 1329.98% quarter-over-quarter from -$0.07 in Q4 2025.
Plus Therapeutics (PSTV) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 12 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.05 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.05, up 96.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 (up 96.52% YoY), and the FY2025 annual result was -$0.29, up 87.61% from the prior year.
- EPS (Weighted Average and Diluted) declined to -$1.05 in Q1 2026 per PSTV's latest filing, from -$0.07 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.01 in Q2 2025 and troughed at -$29.86 in Q1 2025.
- A 5-year average of -$2.76 and a median of -$0.71 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 98.59% in 2025 and fell as far as 3881.33% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.36 in 2022, then soared by 70.34% to -$0.7 in 2023, then climbed by 4.29% to -$0.67 in 2024, then soared by 89.04% to -$0.07 in 2025, then plunged by 1329.98% to -$1.05 in 2026.
- Business Quant data shows PSTV's EPS (Weighted Average and Diluted) at -$1.05 in Q1 2026, -$0.07 in Q4 2025, and -$0.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | -1.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.05 |
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -0.04 |
| Jun 30, 2025 | -0.01 |
| Mar 31, 2025 | -29.86 |
| Dec 31, 2024 | -0.67 |
| Sep 30, 2024 | -0.37 |
| Jun 30, 2024 | -0.71 |
| Mar 31, 2024 | -0.75 |
| Dec 31, 2023 | -0.70 |
| Sep 30, 2023 | -1.00 |
| Jun 30, 2023 | -0.59 |
| Mar 31, 2023 | -2.07 |
| Dec 31, 2022 | -2.36 |
| Sep 30, 2022 | -2.85 |
| Jun 30, 2022 | -3.56 |
| Mar 31, 2022 | -0.19 |
| Dec 31, 2021 | -0.27 |
| Sep 30, 2021 | -0.28 |
| Jun 30, 2021 | -0.25 |